U-Systems was acquired by GE Healthcare Limited in November 2012, having developed and commercialized a breakthrough ultrasound system for greater breast cancer detection.

Think Research

Think Research develops knowledge-based and leading clinical content tools that empower clinicians to deliver the best evidence-based care to patients and drive greater patient outcomes.

Spinal Kinetics

Spinal Kinetics was acquired by Orthofix in March 2018, having developed advanced artificial discs for degenerative diseases of the spine.

Resonant Medical

Resonant Medical was acquired by Elekta in May 2010, having developed 3D ultrasound non-invasive and non-ionizing image-guided radiotherapy products for the treatment of cancer.


Morphotek was acquired by Eisai in April 2007 for $325 million, with a pipeline of treatments for oncology, inflammatory, and infectious diseases.

KAI Pharmaceuticals

Developer of novel therapeutics for kidney disease, KAI Pharmaceuticals was acquired by Amgen in 2012 for US$315 million.

ISTA Pharmaceuticals

From the time we invested in 2002 to our exit in 2006, ISTA Pharmaceuticals launched 3 products in the United States to treat diseases of the eye.

Guava Technologies

Guava Technologies was acquired by Millipore Inc. in February 2009, having developed and manufactured unique flow cytometry systems.


Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005 for treatment of pain and diseases of the central nervous system.

Corus Pharmaceuticals

Corus Pharmaceuticals, developer of Aztreonam for the treatment of cystic fibrosis and Lidocaine for the treatment of oral corticosteroid-dependent asthma, was acquired by Gilead in August 2006 for $365 million.

Ception Therapeutics

Ception Therapeutics was acquired by Cephalon Inc. in March 2010 for $350 million plus significant future millstones with its lead product which was subsequently approved to treat eosinophilic asthma.


Alveolus, developer of next-generation non-vascular interventional stent technology for use in the lungs was acquired by Merit Medical Systems Inc. in February 2008.


Zymeworks is developing best-in-class bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory disease.


Pharmasset was acquired by Gilead in 2011 for $11 billion, having developed the first oral therapeutic for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

MAKO Surgical Corp

MAKO Surgical developed a minimally invasive, more confident robotic surgical arm for partial knee and total hip arthroplasty and was acquired by Stryker for $1.65 billion in 2013.


Forbius was acquired by Bristol Myers Squibb in August 2020, a company targeting hard-to-drug TFG-beta and EGFR pathways in Fibrosis and Cancer.

ESSA Pharma

ESSA Pharmaceuticals is developing a small molecule therapy to overcome the issue of drug resistance and provide additional benefits for patients with prostate cancer.

Engage Therapeutics

Engage Therapeutics was acquired by UBC for up to US$270 million in June 2020, having developed the first on-demand rescue treatment for the rapid termination of active epileptic seizures.

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals has developed the first oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.

OpSens Medical

OpSens Medical announced its intent to be aquired by Haemonetics for $345 million in October 2023. The company is a pioneer of innovative fiber optic sensing technology offering more accurate diagnostic and treatment solutions for patients with coronary artery disease.

Bardy Diagnostics

Bardy was acquired by Hillrom for $375 million in January 2021, having developed and commercialized the most diagnostically-accurate and patient-friendly cardiac patch and monitoring solutions for patients with cardiovascular disease.

Scroll to Top